Skip to content

Labetalol to Prevent Hypertension and Tachycardia During Fiberoptic Bronchoscopy

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00394537
Enrollment
72
Registered
2006-11-01
Start date
Unknown
Completion date
2007-05-31
Last updated
2007-06-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchoscopy

Brief summary

Passing a bronchoscope through the airways frequently causes a stress response even though patients are sedated. This stress response is usually an increase in pulse and blood pressure, which may have undesirable effects on the heart and circulation. We plan to give patients labetalol (a beta blocker which reduces pulse and blood pressure) in addition to normal sedation, to patients undergoing bronchoscopy in our department.

Interventions

DRUGLabetalol 10mg iv

Sponsors

Rabin Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All patients over 18 years old undergo fiberoptic bronchoscopy in our unit

Exclusion criteria

* inability or refusal to give informed consent * bronchoscopy through an artificial airway * intolerance or allergy to the study drug * bradycardia (HR\<60/min) or hypotension (systolic BP \<100) at screening * pregnancy, * concomitant treatment with diltiazem or verapamil * intention to use propofol as the sedative agent for bronchoscopy.

Design outcomes

Primary

MeasureTime frame
Heart Rate
Systolic Blood Pressure
Diastolic Blood Pressure
Rate pressure product (HR*SBP/100)

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 5, 2026